Intratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice
Open Access
- 1 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 1 (5) , pgac244
Abstract
Confining cytokine exposure to the tumors would greatly enhance cancer immunotherapy safety and efficacy. Immunocytokines, cytokines fused to tumor-targeting antibodies, have been developed with this intention, but without significant clinical success to date. A critical limitation is uptake by receptor-expressing cells in the blood, that decreases the dose at the tumor and engenders toxicity. Small-format immunocytokines, constructed with antibody fragments, are hypothesized to improve tumor specificity due to rapid systemic clearance. However, effective design criteria for small-format immunocytokines need further examination. Here, we engineer small interleukin-2 (IL-2) immunocytokines fused to nanobodies with nanomolar to picomolar affinities for the tumor-specific EIIIB domain of fibronectin (also known as EDB). Upon intravenous delivery into immunocompetent mice, such immunocytokines led to similar tumor growth delay as size-matched untargeted IL-2. Intratumoral (i.t.) delivery imparted improved survival dependent on affinity to EIIIB. I.t. administration offers a promising avenue to deliver small-format immunocytokines, given effective affinity for the tumor microenvironment.Keywords
Funding Information
- National Computational Infrastructure (CA174795)
- National Institute of Biomedical Imaging and Bioengineering (R01EB031082)
- National Cancer Institute (P30-CA14051)
- National Science Foundation (0070319)
- National Institutes of Health (S10 OD016326)
This publication has 50 references indexed in Scilit:
- Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactionsNature Protocols, 2013
- Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC RetentionThe Journal of Immunology, 2012
- High response rate after intratumoral treatment with interleukin‐2Cancer, 2010
- Therapy‐induced antitumor vaccination in neuroblastomas by the combined targeting of IL‐2 and TNFαInternational Journal of Cancer, 2010
- Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T CellsJournal of Immunotherapy, 2009
- A modeling analysis of the effects of molecular size and binding affinity on tumor targetingMolecular Cancer Therapeutics, 2009
- Intratumoral immunocytokine treatment results in enhanced antitumor effectsCancer Immunology, Immunotherapy, 2008
- Tumour vascular targetingNature Reviews Cancer, 2005
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Expression of the Alternatively Spliced EIIIB Segment of FibronectinCell Adhesion and Communication, 1995